title: Topical Sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound.
abstract: BACKGROUND
  Whereas Sulfamylon is effective in treatment of burn wound infection, controversy exists regarding its effect on the healing process.
  
  
  METHODS
  A partial thickness skin donor site wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in rabbits under general anesthesia. Sulfamylon cream (8.5%, BERTEK Pharmaceuticals Inc., Morgantown, W Va) was applied on the wound, with either open or occlusive dressing. The control wound was covered with dressings only. On day 7 after injury, stable isotope tracers were infused to determine the fractional synthetic rate (FSR) of DNA, and FSR and fractional breakdown rate (FBR) of protein in the wound.
  
  
  RESULTS
  In the Sulfamylon-open dressing group, the DNA FSR was 1.3 +/- 0.6%/day, the protein FSR was 8.0 +/- 3.5%/day, and the net protein deposition (FSR - FBR) was -0.3 +/- 3.7%/day. These values were lower (P < .01 to .05) than the corresponding values in the control group (DNA FSR: 2.9 +/- 0.9%/day; protein FSR: 20.5 +/- 8.4%/day; net protein deposition: 7.9 +/- 6.0%/day). Sulfamylon cream selectively inhibited DNA FSR from the de novo base synthesis pathway (2.3 +/- 1.2 vs 0.8 +/- 0.5%/day, P < .05 vs control). With the occlusive dressing Sulfamylon cream did not decrease wound DNA FSR due to a stimulation of the base salvage pathway, but still decreased protein FSR (11.5 +/- 5.1%/day, P < .05 vs control). Histologic slides indicated that Sulfamylon cream inhibited re-epithelialization, collagen formation, and angiogenesis in the wound.
  
  
  CONCLUSIONS
  Topical Sulfamylon cream application inhibited DNA and protein synthesis in the wound, which would be expected to retard the healing process.
authors.affiliation: Metabolism Unit, University of Texas Medical Branch, Galveston, TX, USA.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Zhang
authors.forename: John P
authors.initials: JP
authors.lastname: Heggers
authors.forename: David L
authors.initials: DL
authors.lastname: Chinkes
authors.forename: Steven E
authors.initials: SE
authors.lastname: Wolf
authors.forename: Hal K
authors.initials: HK
authors.lastname: Hawkins
authors.forename: Robert R
authors.initials: RR
authors.lastname: Wolfe
mesh_terms: D000287:Administration, Topical; D000596:Amino Acids / Q000097:blood; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D001458:Bandages; D062109:Dermatologic Surgical Procedures; D019520:Living Donors; D008272:Mafenide / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D023421:Models, Animal; D009779:Occlusive Dressings; D011817:Rabbits; D012867:Skin / Q000293:injuries / Q000473:pathology; D014947:Wounds and Injuries / Q000188:drug therapy*
chemical_list: D000596:Amino Acids; D000891:Anti-Infective Agents, Local; D008272:Mafenide